NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C. announces that a class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of purchasers of Osiris Therapeutics Inc. (NASDAQ:OSIR) on behalf of all persons or entities who acquired Osiris securities during the period from May 12, 2014 through November 16, 2015. Pursuant to applicable law, investors have until January 22, 2016 to file a motion to be appointed as lead plaintiff in the investor lawsuit.
The lawsuit alleges that Osiris materially misstated its revenues from several contracts. On November 16, 2015, the Osiris announced that it needed to restate revenue recognition for three contracts, resulting in decreased revenue for the first three quarters of 2015. On this news, the stock price declined over 21% from $13.99 to $10.97 per share.
If you purchased Osiris securities during the class period, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information, please go to www.bespc.com.